Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
NBIX Price Action
Last 7 days
11.0%
Last 30 days
24.4%
Last 90 days
-21.3%
Trailing 12 Months
-16.0%
NBIX RSI Chart
NBIX Valuation
NBIX Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
NBIX Fundamentals
NBIX Revenue
NBIX Earnings
NBIX Profitability
NBIX Investor Care
NBIX Alerts
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 2.4B | 0 | 0 | 0 |
| 2024 | 2.0B | 2.1B | 2.2B | 2.4B |
| 2023 | 1.6B | 1.7B | 1.8B | 1.9B |
| 2022 | 1.2B | 1.3B | 1.4B | 1.5B |
| 2021 | 1.0B | 1.0B | 1.1B | 1.1B |
| 2020 | 886.8M | 1.0B | 1.0B | 1.0B |
| 2019 | 518.6M | 605.1M | 675.5M | 788.1M |
| 2018 | 232.7M | 323.3M | 414.3M | 451.2M |
| 2017 | 0 | 6.3M | 67.1M | 161.6M |
| 2016 | 15.0M | 15.0M | 15.0M | 15.0M |
| 2015 | 22.0M | 21.2M | 20.5M | 19.8M |
| 2013 | 40.6M | 28.0M | 15.5M | 2.9M |
| 2012 | 76.2M | 74.6M | 42.3M | 53.1M |
| 2011 | 45.3M | 52.8M | 80.0M | 77.4M |
| 2010 | 0 | 13.1M | 23.3M | 33.5M |
| 2009 | 0 | 0 | 0 | 3.0M |
Get all data in R, Python etc through our Historical Stock Data APIs
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its products include INGREZZA and DYSVAL, for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, used as an adjunctive therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women, as well as ALKINDI SPRINKLE, for the treatment of pediatric adrenal insufficiency. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-1117568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; Sentia Medical Sciences Inc.; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| CEO | Dr. Kevin C. Gorman Ph.D. |
|---|---|
| WEBSITE | neurocrine.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers Specialty & Generic |
| EMPLOYEES | 1350 |
